A Single-center, Single-arm Phase II Clinical Study Based on FAPI-PET/CT Technology to Predict Pathological Complete Response After Neoadjuvant Chemoradiotherapy for MSS Rectal Cancer
Latest Information Update: 17 Apr 2025
At a glance
- Drugs Capecitabine (Primary) ; Oxaliplatin (Primary) ; Radiopharmaceutical diagnostics (Primary) ; Sintilimab (Primary)
- Indications Adenocarcinoma; Rectal cancer
- Focus Diagnostic use
Most Recent Events
- 09 Apr 2025 Planned initiation date changed from 18 Mar 2025 to 7 Apr 2025.
- 21 Mar 2025 Planned initiation date changed from 1 Oct 2024 to 18 Mar 2025.
- 21 Mar 2025 Status changed from not yet recruiting to recruiting.